Trial Profile

A Phase 2, Multi-center, Randomized, Double-Blind, Parallel-Group, Dose-Finding Study to Assess the Effect of Four Doses of MM120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 06 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lysergide (Primary)
Indications Generalised anxiety disorder
Focus Therapeutic Use
Acronyms MMED008
Sponsors Definium Therapeutics; Mindmed

Most Recent Events

12 Jan 2026 According to Definium Therapeutics media release, MindMed is now called as Definium Therapeutics.
04 Sep 2025 Results published in a MindMed media release
04 Sep 2025 According to a MindMed media release, the company today announced that JAMA has published the full results from its positive Phase 2b study of MM120 in adults with moderate-to-severe generalized anxiety disorder (GAD).

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com